Skip to main content

Market Overview

Risk Should Already Be Priced In Quorum Health Shares

Share:
Risk Should Already Be Priced In Quorum Health Shares

Morgan Stanley has started Quorum Health Corp (NYSE: QHC) with an Equal-Weight rating and $12 price target, saying that risk is already priced in to the shares.

Quorum Health, which owns/leases a portfolio of 38 hospitals across 16 states, is a spun-off company from Community Health Systems (NYSE: CYH).

"We think QHC is starting in a difficult position given the composition of its current portfolio and high leverage levels but risk looks priced in. QHC will benefit from portfolio rationalization, freeing up capacity for accretive acquisitions," analyst Andrew Schenker explained.

"With QHC currently trading at ~6.0x our 2017 EBITDA estimates, versus a range of 6.5x to 8.2x for its peers, we believe the challenges are sufficiently discounted in the stock," the analyst continued.

Related Link: Raymond James Cuts Community Health, Warns QHC Spinoff Makes No Financial Sense

According to the note, the company has its share of challenges including "weaker EBITDA margins, soft utilization, and limited exposure to economic growth."

Specifically, the analyst noted that QHC's 2015 EBITDA margins stands 12.2 percent versus the peer average of 14.9 percent and has posted the softest volumes of his coverage, including closest peer LifePoint Health Inc (NASDAQ: LPNT).

Future volumes should benefit as Quorum Health would focus on expanding physician and capital investments. In addition, Schenker said a renewed focus, room for consolidation in rural markets and Medicaid expansion should fuel growth.

"[W]hile QHC has already realized significant benefits from Medicaid expansion, reform still remains an opportunity as our analysis suggests 47% of Quorum pre-ACA cost of care to the uninsured was delivered in states that have not opted to expand," Schenker elaborated.

The analyst expects Quorum Health "to drive EBITDA growth of -3.1 percent, 1.9 percent and 1.5 percent from 2016 to 2018 before factoring potential M&A."

Latest Ratings for CYH

DateFirmActionFromTo
Dec 2021B of A SecuritiesUpgradesUnderperformBuy
Oct 2021Credit SuisseMaintainsNeutral
Sep 2021UBSInitiates Coverage OnNeutral

View More Analyst Ratings for CYH

View the Latest Analyst Ratings

 

Related Articles (LPNT + CYH)

View Comments and Join the Discussion!

Posted-In: Analyst Color Long Ideas Health Care Price Target Initiation Analyst Ratings Trading Ideas General

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com